Correlation Between Orissa Minerals and Krebs Biochemicals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Orissa Minerals and Krebs Biochemicals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Orissa Minerals and Krebs Biochemicals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between The Orissa Minerals and Krebs Biochemicals and, you can compare the effects of market volatilities on Orissa Minerals and Krebs Biochemicals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Orissa Minerals with a short position of Krebs Biochemicals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Orissa Minerals and Krebs Biochemicals.

Diversification Opportunities for Orissa Minerals and Krebs Biochemicals

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Orissa and Krebs is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding The Orissa Minerals and Krebs Biochemicals and in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Krebs Biochemicals and and Orissa Minerals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on The Orissa Minerals are associated (or correlated) with Krebs Biochemicals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Krebs Biochemicals and has no effect on the direction of Orissa Minerals i.e., Orissa Minerals and Krebs Biochemicals go up and down completely randomly.

Pair Corralation between Orissa Minerals and Krebs Biochemicals

Assuming the 90 days trading horizon The Orissa Minerals is expected to under-perform the Krebs Biochemicals. But the stock apears to be less risky and, when comparing its historical volatility, The Orissa Minerals is 1.34 times less risky than Krebs Biochemicals. The stock trades about -0.19 of its potential returns per unit of risk. The Krebs Biochemicals and is currently generating about -0.11 of returns per unit of risk over similar time horizon. If you would invest  9,167  in Krebs Biochemicals and on December 28, 2024 and sell it today you would lose (2,206) from holding Krebs Biochemicals and or give up 24.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

The Orissa Minerals  vs.  Krebs Biochemicals and

 Performance 
       Timeline  
Orissa Minerals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days The Orissa Minerals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Krebs Biochemicals and 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Krebs Biochemicals and has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Orissa Minerals and Krebs Biochemicals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Orissa Minerals and Krebs Biochemicals

The main advantage of trading using opposite Orissa Minerals and Krebs Biochemicals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Orissa Minerals position performs unexpectedly, Krebs Biochemicals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krebs Biochemicals will offset losses from the drop in Krebs Biochemicals' long position.
The idea behind The Orissa Minerals and Krebs Biochemicals and pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bonds Directory
Find actively traded corporate debentures issued by US companies